Navigation Links
Quintessence Secures Financing

MADISON, WI. - Quintessence Biosciences, Inc., a biotechnology company developing pharmaceutical products for use in research, has finalized a three million dollar financing deal. The majority of the funding, $2.3 million, was received from individual investors, and the remainder was borrowed from the Madison Development Corporation, Wisconsin Department of Commerce, and m2 Lease Funds, a private ......

Full article >>> as received, it has been placed in the exciting position of entering the marketplace with highly sought new tools for protein research.

One of the projects of Quintessence Biosciences is the formulation of multivalent drugs. Multivalent drugs are a new class of medications able to attach to pathogens with several binding sites, enabling them to be precise enough tools to treat a wide va......

Full article >>> ged cartilage or ligaments. Also, collagen is also required for the healing of wounds; products using synthetic collagen could assist in wound treatment.

"Its worth noting that both Quintessence and Nutra-Park, which also announced a round of financing last Thursday, were presenters at the November 2002 Wisconsin Life Sciences Venture Conference sponsored by the Wisconsin Technology Coun......

Full article >>>
'"/>

Source:wistechnology.com By Jamie Lyn Hofmeister 05/28/03


Related biology technology :

1. Quintessence Biosciences advances cancer drug
2. Quintessence Biosciences names new president
3. Quintessence cancer treatment chosen for clinical studies
4. Quintessence division to develop drug tests with NIH grant
5. Quintessence Biosciences forms cancer therapeutic advisory board
6. nPoint Secures Second Round of Funding
7. Financing life science: The ongoing saga
8. Financing of biotech companies so far in 2005: A Midwest odyssey
9. Seed-Stage Venture Financing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps ... and North America this May on the following dates: , ?    London, ... Taylor, Chairman of the Learning and Performance Institute will be the opening ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... supplier of Common Lisp (CL) development tools, and market leader for Semantic ... key performance enhancements now available within the most effective system for developing and ...
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced TĀ·rejĀ·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):